Palbociclib(125.000Mg) shortage status
No active shortage currently reported by the regulators Mederti tracks.
Last updated 22 Feb 2026 · sourced from official medicines regulators
- Generic name (INN)
- Palbociclib(125.000Mg)
- Brand names
- Ibrance
- Class
- Auto-created by Health Sciences Authority — Singapore Post-Registration Actions scraper
Recent shortage history
- Singapore: resolved 26 Mar 2025 (began 26 Mar 2025)
- Singapore: resolved 17 Mar 2025 (began 17 Mar 2025)
Frequently asked questions
Is Palbociclib(125.000Mg) currently in shortage?
No active shortage of Palbociclib(125.000Mg) is currently reported by any of the national medicines regulators Mederti tracks. Shortages can emerge quickly — this page updates daily from official sources.
Where does this Palbociclib(125.000Mg) shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ official regulators across 35+ countries and never publishes unsourced shortage claims.
Get alerted when Palbociclib(125.000Mg) status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.